-
MSD Partners with Hanmi Pharmaceutical to Develop Combination Therapy for Solid Tumors
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with South Korea’s Hanmi Pharmaceutical (KRX: 128940) to develop a combination therapy using MSD’s top-selling anti-PD-1 therapy Keytruda (pembrolizumab) and Hanmi’s bispecific antibody (BsAb) BH3120 for the treatment of progressive or metastatic solid tumors. The financial details of the…
-
Sichuan Kelun Pharmaceutical Reports 12.69% YOY Revenue Growth in 2023 Financial Results
•
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a leading pharmaceutical company in China, has announced its financial results for 2023, with revenues reaching RMB 21.454 billion (USD 2.96 billion), marking a 12.69% year-on-year (YOY) increase, and a net profit of RMB 2.457 billion (USD 340 million). The company’s research and…
-
China Unveils 16-Measure Policy to Support Overseas Investment in Domestic Tech Firms
•
A coalition of 10 Chinese government bureaus, including the Ministry of Commerce, Ministry of Foreign Affairs, National Development and Reform Commission, Ministry of Science and Technology, and Ministry of Industry and Information Technology, have jointly issued a comprehensive policy to bolster overseas institutions investing in domestic technology companies. The policy…
-
Sanofi’s Rilzabrutinib Meets Primary Endpoint in Phase III ITP Trial
•
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its Phase III trial for rilzabrutinib, a potential best-in-class BTK inhibitor, has successfully met its primary endpoint of durable platelet response in patients with immune thrombocytopenia (ITP). The trial also produced positive results in key secondary endpoints and did not raise…
-
China’s CSRC Unveils 16 Measures to Boost Capital Market and Tech Enterprises
•
The China Securities Regulatory Commission (CSRC) has introduced a comprehensive set of 16 measures aimed at enhancing the capital market’s functionality, optimizing resource allocation, and bolstering the high-level development of technology enterprises.
-
Novartis Reports 11% YOY Sales Growth in Q1 2024, Led by Entresto and Cosentyx
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported an 11% year-on-year (YOY) increase in constant currency terms during the first quarter of 2024, reaching USD 11.8 billion in sales. The growth was driven by strong performances across all key brands and geographies. The top-selling and growth-driving drugs included hypertension therapy…
-
Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease
•
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released its financial report for 2023, reporting revenues of RMB 7.98 billion (USD 1.1 billion), a decrease of 24.78% year-on-year (YOY). The net profit attributable to shareholders of the listed company was RMB 1.26 billion (USD…
-
European Commission Approves Pfizer’s Antibiotic Emblaveo for Multiple Indications
•
The European Commission (EC) has granted approval for Pfizer’s (NYSE: PFE) antibiotic Emblaveo (aztreonam + avibactam) for the treatment of complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), complicated urinary tract infections (cUTI), and infections caused by aerobic Gram-negative organisms in adults. The drug was reviewed under an accelerated assessment process…
